Luca Lalli

List of Publications by Year
in descending order

15	586	1163117	1058476
papers	citations	8	14
		h-index	g-index

16	16	16	977
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. Journal of Clinical Investigation, 2018, 128, 5505-5516.	8.2	193
2	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	9.4	124
3	Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures. Journal of Surgical Oncology, 2016, 113, 708-714.	1.7	94
4	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Cancer Journal (Sudbury, Mass), 2017, 23, 86-91.	2.0	71
5	Extracellular vesicles in anti-tumor immunity. Seminars in Cancer Biology, 2022, 86, 64-79.	9.6	21
6	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Cell Communication and Signaling, 2020, 18, 156.	6.5	18
7	The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients. Cancers, 2021, 13, 4157.	3.7	17
8	Nutritional status and body composition assessment in patients with a new diagnosis of advanced solid tumour: Exploratory comparison of computed tomography and bioelectrical impedance analysis. Clinical Nutrition, 2021, 40, 1268-1273.	5.0	12
9	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
10	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. Journal of Investigative Dermatology, 2022, 142, 3030-3040.e5.	0.7	6
11	FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods. Tumori, 2017, 103, 360-366.	1.1	5
12	Risk assessment of thromboembolic events in hospitalized cancer patients. Scientific Reports, 2021, 11, 18200.	3.3	5
13	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET). Clinical Cancer Research, 2021, 27, 3443-3455.	7.0	4
14	Integrated transcriptional–phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine, 2021, 11, e434.	4.0	3
15	Selective modulation of immune transcripts in extracellular vesicles from plasma of renal cell carcinoma patients receiving nivolumab.. Journal of Clinical Oncology, 2020, 38, 719-719.	1.6	1